PMV Pharmaceuticals, Inc. (PMVP) stock
PMVPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.22+0.03 (+2.52%)
Close on Nov 17, 2026Market cap $65.22MP/E –Yield –
PMV Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
PMV Pharmaceuticals's cash was $79.43M at Jun 30, 2026. For fiscal 2025 it was $112.94M, down 38.4% from the year before. The highest annual figure on record is $361.42M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.94M | -38.4% |
| FY2024 | Dec 31, 2024 | $183.30M | -19.8% |
| FY2023 | Dec 31, 2023 | $228.56M | -6.2% |
| FY2022 | Dec 31, 2022 | $243.55M | -22.5% |
| FY2021 | Dec 31, 2021 | $314.07M | -13.1% |
| FY2020 | Dec 31, 2020 | $361.42M | +256.1% |
| FY2019 | Dec 31, 2019 | $101.49M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $79.43M | -46.4% |
| Q1 FY2026 | Mar 31, 2026 | $93.55M | -43.6% |
| Q4 FY2025 | Dec 31, 2025 | $112.94M | -38.4% |
| Q3 FY2025 | Sep 30, 2025 | $129.25M | -34.7% |
| Q2 FY2025 | Jun 30, 2025 | $148.31M | -30.3% |
| Q1 FY2025 | Mar 31, 2025 | $165.82M | -22.2% |
| Q4 FY2024 | Dec 31, 2024 | $183.30M | -19.8% |
| Q3 FY2024 | Sep 30, 2024 | $197.94M | -16.9% |
| Q2 FY2024 | Jun 30, 2024 | $212.92M | -2.7% |
| Q1 FY2024 | Mar 31, 2024 | $213.06M | -7.1% |
| Q4 FY2023 | Dec 31, 2023 | $228.56M | -6.2% |
| Q3 FY2023 | Sep 30, 2023 | $238.10M | -8.0% |
| Q2 FY2023 | Jun 30, 2023 | $218.84M | -21.1% |
| Q1 FY2023 | Mar 31, 2023 | $229.43M | -22.2% |
| Q4 FY2022 | Dec 31, 2022 | $243.55M | -22.5% |
| Q3 FY2022 | Sep 30, 2022 | $258.86M | -15.9% |
| Q2 FY2022 | Jun 30, 2022 | $277.43M | -12.9% |
| Q1 FY2022 | Mar 31, 2022 | $294.77M | -11.1% |
| Q4 FY2021 | Dec 31, 2021 | $314.07M | -13.1% |
| Q3 FY2021 | Sep 30, 2021 | $307.65M | -17.6% |
| Q2 FY2021 | Jun 30, 2021 | $318.35M | +213.7% |
| Q1 FY2021 | Mar 31, 2021 | $331.49M | – |
| Q4 FY2020 | Dec 31, 2020 | $361.42M | – |
| Q3 FY2020 | Sep 30, 2020 | $373.15M | – |
| Q4 FY2019 | Dec 31, 2019 | $101.49M | – |
See a number that looks wrong?